Friday, January 11, 2019
Halozyme undervalued relative to ‘de -risked’ assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week’s update and 2019 outlook. The analyst continues to view the company as undervalued relative to its “highly de -risked” lead Enhanze assets. He sees “significant option value” to the broader Enhanze opportunity and PEGPH20 data.
https://thefly.com/landingPageNews.php?id=2847405
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.